Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 3:28 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,012 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adverse Events Clear all
Completed No phase listed Observational

Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing

NCT01031641
View directory record Official record
Conditions
Lymphomas, Leukemias, Multiple Cancers
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
1,448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Nov 1, 2026, 3:28 AM EST
Completed Phase 2 Interventional

Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions

NCT05721729
View directory record Official record
Conditions
Postbariatric Hypoglycemia
Interventions
Mizagliflozin, Placebo
Drug
Lead sponsor
Vogenx, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Palo Alto, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Nov 1, 2026, 3:28 AM EST
Active, not recruiting No phase listed Observational

Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment

NCT05926024
View directory record Official record
Conditions
Breast Cancer
Interventions
Exercise Recall Patient Reported Outcomes, Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes, Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Patient Reported Outcomes, Patient Reported Outcomes PROMIS Cognitive Function (Short Form 8a), Patient Reported Outcomes Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12), Patient Reported Outcomes PROMIS, Patient Reported Outcomes FACT-Endocrine Symptoms, Patient Reported Outcomes Penn Arthralgia Aging Survey, Patient Reported Outcomes PRO-CTCAE (patient-reported CTCAE), p16 tumor suppressor gene
Behavioral · Diagnostic Test
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Nov 1, 2026, 3:28 AM EST
Active, not recruiting Phase 1 Interventional

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

NCT05308654
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
ABBV-453, Dexamethasone, Daratumumab, Lenalidomide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Stanford, California • Miami, Florida • New Orleans, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Nov 1, 2026, 3:28 AM EST
Completed Not applicable Interventional Results available

Retrospective Independent Safety Review of Closed Irrisept Study

NCT05359666
View directory record Official record
Conditions
Adverse Events
Interventions
Irrisept, Standard of Care
Device
Lead sponsor
Irrimax Corporation
Industry
Eligibility
Not listed
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Nov 1, 2026, 3:28 AM EST
Not listed Phase 4 Interventional

Pre-Operative Ketamine Infusion for Post Operative Pain Control After Revision Spinal Surgery

NCT06066879
View directory record Official record
Conditions
Revision Spine Surgery, Fusion of Spine, Cervical Fusion, Lumbar Fusion
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
AXIS Spine Center- a division of Northwest Specialty Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Coeur d'Alene, Idaho
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Nov 1, 2026, 3:28 AM EST
Withdrawn Phase 2 Interventional

A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients

NCT03541486
View directory record Official record
Conditions
Pancreatic Neoplasm
Interventions
Ascorbate, Gemcitabine, radiation therapy
Drug · Radiation
Lead sponsor
Joseph J. Cullen, MD, FACS
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Nov 1, 2026, 3:28 AM EST
Recruiting No phase listed Observational

Global Cardio Oncology Registry

NCT05598879
View directory record Official record
Conditions
Breast Cancer, Hematologic Malignancy, Immune Checkpoint Inhibitor-Related Myocarditis, Cardiotoxicity, Cardiovascular Diseases
Interventions
anonymized data collection during programmed surveillance clinical follow up
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Nov 1, 2026, 3:28 AM EST
Recruiting No phase listed Observational

Drug-Induced Liver Injury (DILI) Network Retrospective

NCT00360646
View directory record Official record
Conditions
Drug Induced Liver Injury
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
2 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Indianapolis, Indiana • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Nov 1, 2026, 3:28 AM EST
Completed No phase listed Observational

Electronic Prescribing and Electronic Transmission of Discharge Medication Lists

NCT00603070
View directory record Official record
Conditions
Medication Errors
Interventions
E-prescribing system, Electronic transmission of medication discharge lists
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Nov 1, 2026, 3:28 AM EST
Completed Not applicable Interventional Results available

Using the Active Breathing Control Device to Reduce Radiation Side Effects to Critical Structures in Breast Cancer

NCT00328783
View directory record Official record
Conditions
Breast Cancer
Interventions
Active Breathing Coordinator (ABC), Radiation Therapy
Device · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Nov 1, 2026, 3:28 AM EST
Terminated Not applicable Interventional

Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Capecitabine Chemotherapy

NCT00767689
View directory record Official record
Conditions
Hand and Foot Syndrome
Interventions
Vitamin B 6, placebo
Drug
Lead sponsor
Cook County Health
Government
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Nov 1, 2026, 3:28 AM EST
Recruiting Not applicable Interventional

Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial

NCT04419480
View directory record Official record
Conditions
Cardiogenic Shock, Heart Failure, Ambulatory Hemodynamic Monitoring
Interventions
CardioMEMS implantation with routine ambulatory pulmonary artery pressure monitoring and medication optimization
Device
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Nov 1, 2026, 3:28 AM EST
Recruiting Phase 1 Interventional

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

NCT05005403
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer
Interventions
Azirkitug, Budigalimab, Bevacizumab, Telisotuzumab Adizutecan
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
20
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 1, 2026, 3:28 AM EST
Recruiting Not applicable Interventional

Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy

NCT07641361
View directory record Official record
Conditions
Obesity & Overweight, Type 2 Diabetes, Type 2 Diabetes (Adult Onset), Obesity Type 2 Diabetes Mellitus, Dehydration
Interventions
Hydration Plus, Control
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Nov 1, 2026, 3:28 AM EST
Recruiting Phase 1Phase 2 Interventional

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

NCT06158854
View directory record Official record
Conditions
Immunoglobulin Light Chain (AL) Amyloidosis
Interventions
ABBV-383 (Etentamig)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
12
States / cities
Miami, Florida • Boston, Massachusetts • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Nov 1, 2026, 3:28 AM EST
Completed Not applicable Interventional

Trial of Cognitive Behavioral Therapy to Reduce Antiretroviral Therapy Side Effects

NCT00696839
View directory record Official record
Conditions
HIV Infections, Adverse Effects
Interventions
Cognitive-behavioral therapy
Behavioral
Lead sponsor
Duquesne University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Nov 1, 2026, 3:28 AM EST
Completed Phase 2 Interventional Results available

Prebiotics and Metformin Improve Gut and Hormones in Type 2 Diabetes in Youth (MIGHTY-fiber)

NCT04209075
View directory record Official record
Conditions
Diabetes
Interventions
Biomebliss, Metformin, Placebo
Dietary Supplement · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
10 Years to 25 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Nov 1, 2026, 3:28 AM EST
Completed Phase 4 Interventional Results available

Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients

NCT02764697
View directory record Official record
Conditions
Uveitis, Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Scleritis, Clinically Significant Macular Edema
Interventions
H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
Drug
Lead sponsor
Tampa Bay Uveitis Center, LLC
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Nov 1, 2026, 3:28 AM EST
Completed Phase 1 Interventional

Computer-Based Training in Patients With Post-Chemotherapy Cognitive Impairment

NCT00387062
View directory record Official record
Conditions
Breast Cancer, Cognitive Symptoms, Memory Disorders
Interventions
Computer-based Cognitive Training
Device
Lead sponsor
Posit Science Corporation
Industry
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2008 · Synced Nov 1, 2026, 3:28 AM EST
Completed Phase 1 Interventional

Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

NCT00482846
View directory record Official record
Conditions
Mucositis, Multiple Myeloma
Interventions
Palifermin, melphalan, questionnaire administration, autologous peripheral blood stem cell transplantation, quality-of-life assessment
Biological · Drug · Other + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Nov 1, 2026, 3:28 AM EST
Completed Not applicable Interventional

Impact of a Prehospital Sepsis Protocol on Timely Antibiotic Administration and Subsequent Adverse Events

NCT05502107
View directory record Official record
Conditions
Sepsis
Interventions
PRESS Intervention
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
984 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia • Iowa City, Iowa • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Nov 1, 2026, 3:28 AM EST
Not listed No phase listed Observational

National Vaccine Adverse Event Reporting Survey and Etiology

NCT05095844
View directory record Official record
Conditions
COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use, Corona Virus Infection, Blood Clot, Thrombocytopenia, Neuritis, Vasculitis, Influenza, Guillain-Barré, GWAS, Genetic Sequencing
Interventions
vaccinated
Biological
Lead sponsor
Neuroganics LLC
Industry
Eligibility
5 Years to 99 Years
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Northglenn, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Nov 1, 2026, 3:28 AM EST
Terminated Phase 3 Interventional

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

NCT00092287
View directory record Official record
Conditions
Malignant Carcinoid Syndrome
Interventions
lanreotide Autogel (somatostatin analogue), Sandostatin long acting release (LAR) Depot (somatostatin analogue)
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Nov 1, 2026, 3:28 AM EST